Reply to Zhou and Wu, "Be Careful with Adverse Events Caused by Cefoperazone-Sulbactam"

Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02028-19. doi: 10.1128/AAC.02028-19. Print 2020 Jan 27.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Bacterial Agents
  • Cefepime
  • Cefoperazone*
  • Healthcare-Associated Pneumonia
  • Humans
  • Sulbactam*

Substances

  • Anti-Bacterial Agents
  • Cefoperazone
  • Cefepime
  • Sulbactam